股票代码：603351 证券简称：威尔药业 公告编号：2025-015 南京威尔药业集团股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （二）变更前采用的会计政策 本次会计政策变更前，公司执行财政部颁布的《企业会计准则—基本准则》和 各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告以及其他相关 规定。 （三）变更后采用的会计政策 本次会计政策变更后，公司将执行《企业会计准则解释第 17 号》、《企业会计 准则解释第 18 号》的相关规定。其他未变更部分，仍按照财政部前期发布的《企业 会计准则—基本准则》和各项具体会计准则、企业会计准则应用指南、企业会计准 则解释公告以及其他相关规定执行。 南京威尔药业集团股份有限公司（以下简称"公司"）根据中华人民共和国财政 部（以下简称"财政部"）发布的《关于印发<企业会计准则解释第 17 号>的通知》 （财会〔2023〕21 号）及《关于印发<企业会计准则解释第 18 号>的通知》（财会 〔2024〕24 号）的要求，对相关会计政策进行变更 ...

南京威尔药业集团股份有限公司 董事会审计委员会2024年度履职情况报告 南京威尔药业集团股份有限公司 董事会审计委员会 2024 年度履职情况报告 南京威尔药业集团股份有限公司（以下简称"公司"）董事会审计委员会根据中国 证监会《上市公司治理准则》、上海证券交易所《上市公司自律监管指引第1号-规范 运作》及《公司章程》、《董事会审计委员会工作细则》等有关规定，本着勤勉尽责的 态度，认真履行审计监督职责，现将审计委员会 2024 年度履职情况报告如下： 南京威尔药业集团股份有限公司 董事会审计委员会2024年度履职情况报告 1、评估外部审计机构的独立性和专业性 一、董事会审计委员会基本情况 公司第三届董事会审计委员会由 3 名独立董事组成，主任委员由具有专业会计资 格的独立董事管亚梅女士担任。董事会审计委员会成员均具有相关的专业知识和经验， 能够胜任审计委员会的工作，符合上海证券交易所的规定及《公司章程》等要求。 二、审计委员会会议召开情况 2024 年度，公司董事会审计委员会共召开 3 次会议，参加会议的委员本着勤勉尽 责的原则，认真履行职责，积极对相关议题发表专业意见，各项议案均经全体委员审 议通过。具体情 ...

证券代码：603351 证券简称：威尔药业 公告编号：2025-014 南京威尔药业集团股份有限公司关于 一、说明会类型 南京威尔药业集团股份有限公司（以下简称"公司"）已于 2025 年 4 月 22 日发布公司 2024 年度报告及 2025 年第一季度报告，为便于广大投资者更全面深 入地了解公司公司经营成果、财务状况，公司拟召开 2024 年度暨 2025 年第一季 度网上业绩说明会，针对 2024 年度及 2025 年第一季度的经营成果及财务指标的 具体情况与投资者进行互动交流与沟通，在信息披露允许的范围内就投资者关注 的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2025 年 04 月 29 日 上午 10:00-11:00 （二）会议召开地点：上证路演中心（http://roadshow.sseinfo.com/） （三）会议召开方式：上证路演中心网络互动 召开 2024 年度暨 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2 ...

三、分红送配方案情况 10派4元(含税) 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 9314.4万股，累计占流通股比： 68.78%，较上期变化： 276.98万股。 | 持有数量(万股) 名称 | | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 吴仁荣 | 1852.20 | 13.68 | 不变 | | 唐群松 | 1411.20 | 10.42 | 不变 | | 高正松 | 1411.20 | 10.42 | 不变 | | 陈新国 | 1411.20 | 10.42 | 不变 | | 南京舜泰宗华创业投资合伙企业(有限合伙) | 1014.30 | 7.49 | 不变 | | 沈九四 | 690.55 | 5.10 | 不变 | | 国泰佳泰股票专项型养老金产品-招商银行股份有限 公司 | 476.30 | 3.52 | 103.83 | | 全国社保基金一一二组合 | 380.68 | 2.81 | 新进 | | 雷立军 | 368.77 | 2.72 | 39.64 | | 吴荣文 | 298.00 ...

威尔药业（603351）公告，2025年第一季度营收为3.5亿元，同比增长6.03%；净利润为3658.76万元， 同比增长5.73%。 ...

证券代码：603351 证券简称：威尔药业 公告编号：2025-004 南京威尔药业集团股份有限公司（以下简称"公司"）近日收到公司控股股东吴仁 荣先生的函告，获悉其所持有的公司部分股份办理了质押，具体情况如下： | | 是否 | 本次质 | 是否 | 是否 | | | | 占其所 | 占公司 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 为控 | | | | 质押 | 质押 | | | | 融资 | | | | 押股数/ | 为限 | 补充 | | | 质权人 | 持股份 | 总股本 | | | 名称 | 股股 | 万股 | 售股 | 质押 | 起始日 | 到期日 | | 比例 | 比例 | 资金 | | | 东 | | | | | | | | | 用途 | | | | | | | | | 南京证 | | | 个人 | | | | | | | | | 券股份 | | | | | 吴仁荣 | 是 | 857 | 否 | 否 | 2025-3-24 | 2026-3-24 | | 46.27% ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [6][7]. Core Insights - The company is advancing in both pharmaceutical excipients and synthetic lubricant base oils, entering a new development phase. The consistent evaluation of generic drugs is accelerating industry upgrades, with high-end pharmaceutical excipients expected to significantly enhance profits. The company has a stable management structure and is well-positioned to benefit from the growing demand for high-quality excipients and lubricants [6][7]. Financial Data and Profit Forecast - Total revenue is projected to grow from 1,156 million yuan in 2023 to 2,071 million yuan in 2026, with a compound annual growth rate (CAGR) of approximately 20.8% [2]. - Net profit attributable to shareholders is expected to increase from 112 million yuan in 2023 to 236 million yuan in 2026, reflecting a CAGR of about 26.9% [2]. - Earnings per share (EPS) is forecasted to rise from 0.83 yuan in 2023 to 1.74 yuan in 2026 [2]. - The gross margin is anticipated to improve from 27.4% in 2023 to 28.8% in 2026 [2]. Market Data - As of February 17, 2025, the closing price of the stock is 24.61 yuan, with a market capitalization of 3,333 million yuan [3]. - The price-to-earnings (PE) ratio is projected to decrease from 30 in 2023 to 14 in 2026, indicating a favorable valuation trend [2][7]. Business Overview - The company specializes in the research and production of pharmaceutical excipients and synthetic lubricant base oils, utilizing core technologies such as ether polymerization and ester synthesis [18]. - The pharmaceutical excipients market in China is still in its early stages, with a market share of less than 5% in the pharmaceutical formulation industry, indicating significant growth potential [6][36]. Product and Application - Key products include the Tween 80 series, polyethylene glycol series, and propylene glycol, which are widely used in various drug formulations [46][50]. - The company is expanding its product line to include high-end injectable excipients, which are expected to drive revenue growth [46][48]. Competitive Landscape - The pharmaceutical excipients market in China is characterized by a fragmented structure, with many small and non-specialized companies. The company is positioned as a significant player among a few established firms [44][45].

证券代码：603351 证券简称：威尔药业 公告编号：2025-003 发证时间：2024 年 11 月 6 日 本次高新技术企业的认定系原证书有效期满后的重新认定。根据《中华人民共 和国企业所得税法》以及国家对高新技术企业的相关税收优惠政策规定，威尔生物 科技自本次通过高新技术企业认定后连续三年（2024年至2026年）可继续享受高新 技术企业的税收优惠政策，即按照 15% 的税率缴纳企业所得税。 南京威尔药业集团股份有限公司董事会 南京威尔药业集团股份有限公司 由于威尔生物科技 2024 年度已根据相关规定按 15% 的税率预缴企业所得税， 故本次获得高新技术企业重新认定不会对 2024 年度经营业绩产生影响。 关于全资子公司获得高新技术企业重新认定的公告 有效期：三年 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 南京威尔药业集团股份有限公司全资子公司南京威尔生物科技有限公司（以下 简称"威尔生物科技"）近日收到由江苏省科学技术厅、江苏省财政厅、国家税务总 局江苏省税务局联合颁发的《高新技术企业证书》，具体信息如 ...

Financial Performance - The company's operating revenue for Q3 2024 reached ¥312,206,558.92, representing a year-on-year increase of 2.13%[2] - Net profit attributable to shareholders for Q3 2024 was ¥34,002,055.99, up 36.64% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥33,884,294.46, reflecting a 36.69% increase year-on-year[2] - Basic earnings per share for Q3 2024 were ¥0.25, an increase of 31.58% year-on-year[2] - Total operating revenue for Q3 2024 was 128,898,149.74 CNY, an increase from 83,948,045.08 CNY in Q3 2023, representing a growth of approximately 53.5%[14] - Net profit attributable to shareholders of the parent company reached 112,897,296.64 CNY, up from 78,271,460.39 CNY in the same period last year, reflecting a growth of about 44.4%[15] - The total profit for Q3 2024 was 128,731,004.47 CNY, compared to 83,796,714.03 CNY in Q3 2023, representing an increase of approximately 53.5%[14] Cash Flow - The net cash flow from operating activities for Q3 2024 was ¥84,285,195.63, a significant increase of 89.19% compared to the same period last year[2] - The company experienced a significant increase in cash flow due to higher operating revenue, contributing to a year-to-date cash flow increase of 190.11%[5] - Cash flow from operating activities for the first three quarters of 2024 was 161,205,186.32 CNY, significantly higher than 55,567,467.81 CNY in the same period of 2023, marking an increase of about 189%[16] - The company recorded a net cash inflow from operating activities of 842,784,174.82 CNY in the first three quarters of 2024, compared to 617,267,798.70 CNY in the same period of 2023, indicating a growth of about 36.5%[16] Assets and Liabilities - Total assets at the end of Q3 2024 were ¥2,279,437,409.53, a slight increase of 0.02% from the end of the previous year[3] - Shareholders' equity attributable to the parent company increased by 5.41% year-on-year, reaching ¥1,670,212,016.14[3] - The company's total liabilities amounted to RMB 603,601,125.29, down from RMB 686,221,568.07, indicating a decrease of 12.1%[12] - Short-term borrowings decreased to RMB 331,185,736.11 from RMB 362,221,219.44, a reduction of 8.6%[12] - The retained earnings increased to RMB 528,935,171.78 from RMB 456,669,614.74, representing a growth of 15.8%[12] Research and Development - Research and development expenses for Q3 2024 were 47,691,176.39 CNY, compared to 40,564,145.19 CNY in Q3 2023, indicating an increase of approximately 17.5%[14] Investment Activities - The net cash flow from investing activities was -65,505,220.62, compared to -51,549,090.29 in the previous period, indicating an increase in cash outflow for investments[17] - Cash paid for the acquisition of fixed assets and intangible assets was 43,475,153.98, down from 53,159,960.36, indicating a reduction in capital expenditures[17] - The company reported a cash outflow of 1,400,000.00 related to other investment activities, down from 2,050,000.00, suggesting a decrease in ancillary investment costs[17] Financing Activities - Cash inflow from financing activities totaled 242,886,361.11, down from 365,339,633.34 in the previous period, reflecting a decrease in financing received[17] - Cash outflow for debt repayment was 268,300,000.00, an increase from 241,020,000.00 in the previous period, showing higher debt servicing costs[17] - The net cash flow from financing activities was -84,016,668.97, a significant decline from a positive cash flow of 68,540,370.35 in the previous period, indicating a shift in financing strategy[17] Other Information - The company has not reported any significant changes in major shareholders or their participation in margin trading[10] - There are no new product launches or technological developments mentioned in the report[10]

证券代码：603351 证券简称：威尔药业 公告编号：2024-028 南京威尔药业集团股份有限公司 关于公司2024年第三季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 南京威尔药业集团股份有限公司（以下简称"公司"）主营业务为药用辅料及合 成润滑基础油产品的研发、生产和销售。根据上海证券交易所发布的《上市公司行 业信息披露指引第十四号－化工》等文件要求，现将公司 2024 年第三季度主要经营 数据公告如下： | 主要产品 | 2024 年 1-9 月 | | 2024 年 | 1-9 月 | 2024 年 | 1-9 月 | | --- | --- | --- | --- | --- | --- | --- | | | 生产量（吨） | | 销售量（吨） | | 销售收入（万元） | | | 1、合成润滑基础油 | | 45,940.16 | | 44,195.45 | | 69,541.45 | | 其中：机械类 | | 29,608.14 | | 28,904.49 | | 51,622. ...